The firm said that its platform successfully detected pathogens and resistance markers at limits of detection as low as 1 CFU/ml in spiked blood samples.
As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.
Under the contract, DNAe will develop tests for antimicrobial resistant infections and influenza that it submits to the FDA for clearance.
The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.
The company is also developing a next-generation sequencing product that may be applied at the point of need to test for bloodstream infections and later as a liquid biopsy for cancer.
The London-based firm plans to fund development and clinical trials for its point-of-care diagnostic test for serious blood infections.
DNAe will combine its semiconductor DNA sequencing technology with nanoMR's PCS technology for a complete blood-to-result solution.
NEW YORK (GenomeWeb) – London-based DNA Electronics is developing a point-of-care diagnostic platform that can amplify, genotype via real-time PCR, and do targeted semiconductor sequencing all on one chip.
Cepheid said this week that it has appointed Peter Farrell as executive vice president of international commercial operations.
The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.
A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.
Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.
In Science this week: analysis of DNA from ancient North Africans, and more.